Renaissance Technologies (RenTech)'s BBOT Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 58,600 shares of BridgeBio Oncology Therapeutics, Inc. (BBOT) worth $446,532, representing 0.00% of the portfolio. First purchased in 2025-Q4, this short-term holding has been held for 3 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained this position in BBOT for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2026, adding 27,600 shares. Largest reduction occurred in Q2 2026, reducing 43,300 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s BridgeBio Oncology Therapeutics (BBOT) Holding Value Over Time
Track share changes against reported price movement
Quarterly BridgeBio Oncology Therapeutics (BBOT) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | -43,300 | Reduce 42.49% | 58,600 | $7.62 |
| Q1 2026 | +27,600 | Add 37.15% | 101,900 | $8.95 |
| Q4 2025 | +74,300 | New Buy | 74,300 | $12.52 |
Renaissance Technologies (RenTech)'s BridgeBio Oncology Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased BridgeBio Oncology Therapeutics, Inc. (BBOT) in Q4 2025, acquiring 74,300 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held BridgeBio Oncology Therapeutics, Inc. (BBOT) for 3 quarters since Q4 2025.
Renaissance Technologies (RenTech)'s largest addition to BridgeBio Oncology Therapeutics, Inc. (BBOT) was in Q4 2025, adding 74,300 shares worth $930,236.
According to the latest 13F filing for Q2 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 58,600 shares of BridgeBio Oncology Therapeutics, Inc. (BBOT), valued at approximately $446,532.
As of the Q2 2026 filing, BridgeBio Oncology Therapeutics, Inc. (BBOT) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in BridgeBio Oncology Therapeutics, Inc. (BBOT) was 101,900 shares, as reported at the end of Q1 2026.